Gastroenteropancreatic Neuroendocrine Neoplasm clinical trials at UCSF
1 in progress, 0 open to eligible people
Showing trials for
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
Sorry, not yet accepting patients
This is a multicenter, randomized, open-label, phase III study comparing standard of care use of somatostatin analogues (SSAs) to standard of care observation in patients with neuroendocrine neoplasms following treatment with Peptide Receptor Radionuclide Therapy (PRRT) (ethanol-stabilized Lu-177 dotatate).
San Francisco, California and other locations
Our lead scientists for Gastroenteropancreatic Neuroendocrine Neoplasm research studies include Thomas Hope, MD.
Last updated: